ai3Bio raises $48m Series A for autoimmune therapy development
Founding investors UPMC Enterprises and Ziff Capital Partners led the financing, with Cockrell Interests and Tanis Ventures backing the next development stage.
Preparing the programmes for human trials
The $48 million financing will support both of ai3Bio’s therapeutic platforms, including IND-enabling studies intended to prepare its autoimmune disease programmes for first-in-human testing.
The round brings further backing from founding investors UPMC Enterprises and Ziff Capital Partners, alongside Cockrell Interests and Tanis Ventures. The development work centres on moving the company’s immune-cell targeting approaches through the studies required before clinical trials.
Use of funds
Advance IND-enabling studies toward first-in-human trials for autoimmune disease programs
Advance both therapeutic platforms